Retatrutide may well be the therapy that bridges the gap between cutting-edge research and real-world transformationsignaling the future of personalized metabolic care
There are three GLP-1 drugs that the FDA has approved for the treatment of obesity: Zepbound (tirzepatide), Saxenda (liraglutide), and Wegovy (semaglutide)
Prescription GLP-1 receptor agonists undergo rigorous testing for safety and efficacy, while most over-the-counter supplements lack the same level of scientific validation and regulation
For example, if a patient maintains stable weight reduction for a year but then loses more weight after 6 months on the same GLP-1RA dose, secondary causes should be investigated, especially due to a higher malignancy risk in patients with obesity
Retatrutide has been associated with reductions in triglycerides in trial data, whereas elevated GH levels from tesamorelin can alter fatty acid mobilisation
If the drops have been stored properly in the refrigerator, they should maintain potency until this date
